hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06344364 id: PHN 1-080-23 briefTitle: Digital Pathology and AI for Liver Outcomes in MASLD acronym: DPAILO-1 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-03 date: 2024-04-08 name: PharmaNest, Inc class: INDUSTRY name: Chinese University of Hong Kong name: University of Edinburgh name: University of Seville name: Imperial College London name: Icahn School of Medicine at Mount Sinai name: Fundacio Clinic Barcelona briefSummary: The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital pathology liver biopsy images, in predicting clinical hepatic decompensation events in patients with metabolic dysfunction-associated steatohepatitis (MASH). conditions: Metabolic Dysfunction-associated Steatotic Liver Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2000 type: ESTIMATED name: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS) measure: Performance of Hepatic Decompensation Event predictive value of the FibroNest Ph-FCS measure: Performance of Hepatic Decompensation Event predictive value of the FIB-4 biomarker, a non-invasive test measure: Performance of Hepatic Decompensation Event predictive value of the elastography (Fibroscan) biomarker, a non-invasive test measure: Performance of Hepatic Decompensation Event predictive value of the FibroNest Parenchymal Tissue Adjusted Phenotypic Fibrosis Composite Score (Pt-Ph-FCS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Icahn School of Medicine at Mount Sinai city: New York state: New York zip: 10029 country: United States name: Meena Bansal, MD role: CONTACT email: meena.bansal@mssm.edu lat: 40.71427 lon: -74.00597 facility: The Chinese University of Hong Kong city: Sha Tin country: Hong Kong name: Vincent Wong, PhD role: CONTACT email: wongv@cuhk.edu.hk lat: 22.38333 lon: 114.18333 facility: Fundació de Recerca Clinic Barcelona city: Barcelona country: Spain name: Isabel Graupera, PhD role: CONTACT email: igraupera@hsph.harvard.edu lat: 41.38879 lon: 2.15899 facility: University of Seville city: Sevilla zip: 41004 country: Spain name: Manuel R Gómez, PhD role: CONTACT email: mromerogomez@us.es lat: 37.38283 lon: -5.97317 facility: University of Edinburgh city: Edinburgh state: Scotland country: United Kingdom name: Jonathan Fallowfield, PhD role: CONTACT email: Jonathan.Fallowfield@ed.ac.uk name: Timothy Kendall, PhD role: CONTACT email: Tim.Kendall@ed.ac.uk lat: 55.95206 lon: -3.19648 facility: University of Edinburgh city: Edinburgh state: Scotland country: United Kingdom name: Quentin Anstee, PhD role: CONTACT email: quentin.anstee@newcastle.ac.uk name: Jo Boyle role: CONTACT email: jo.boyle@newcastle.ac.uk lat: 55.95206 lon: -3.19648 facility: Imperial College London city: London country: United Kingdom name: Pinelopi Manousou, PhD role: CONTACT email: p.manousou@imperial.ac.uk lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06344351 id: TQB3006-I-01 briefTitle: A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer overallStatus: RECRUITING date: 2024-04-25 date: 2025-03 date: 2026-08 date: 2024-04-03 date: 2024-04-26 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer. conditions: Advanced Malignant Neoplasm studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 93 type: ESTIMATED name: TQB3006 tablets measure: Dose limiting toxicity (DLT) measure: Maximum tolerated dose (MTD) measure: Recommended phase II dose (RP2D) measure: Adverse events (AE) measure: Serious adverse events (SAE) measure: Time to reach maximum plasma concentration (Tmax) measure: Peak concentration (Cmax) measure: Half-life (t1/2) measure: Area under the concentration-time curve (AUC [0-infinity]) measure: Area under the concentration-time curve (AUC [0-t]) measure: Apparent clearance (CL/F) measure: Apparent volume of distribution (Vd/F) measure: Objective response rate (ORR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Harbin Medical University Cancer Hospital status: RECRUITING city: Harbin state: Heilongjiang zip: 150000 country: China name: Tongsen Zheng, Doctor role: CONTACT phone: 15134569619 email: zhengtongsen@126.com lat: 45.75 lon: 126.65 hasResults: False
nctId: NCT06344338 id: Z211100002921030 briefTitle: Application of tDCS Stimulation in Controlling Refractory Status Epilepticus acronym: tDCS overallStatus: RECRUITING date: 2024-03-31 date: 2024-12-31 date: 2025-03-31 date: 2024-04-03 date: 2024-04-03 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus conditions: Refractory Status Epilepticus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The patients who meet the eligibility requirements will be randomized in a 1:1 ratio to undergo targeting tDCS stimulation (up to 10 times) or sham stimulation primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 32 type: ESTIMATED name: tDCS stimulation name: TDCS sham-stimulation measure: Number of participants with status epilepticus termination between tDCS treatment group and tDCS sham--stimulation group as assessed by Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus measure: Number of participants with treatment-related adverse events between tDCS treatment group and tDCS sham--stimulation group sex: ALL minimumAge: 14 Years maximumAge: 80 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Xuanwu Hospital, Capital Medical University status: RECRUITING city: Beijing state: Beijing zip: 100053 country: China name: Weibi Chen role: CONTACT phone: +8615010255903 email: chenweibi@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06344325 id: EDPP briefTitle: ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-31 date: 2026-03-31 date: 2024-04-03 date: 2024-04-19 name: Tongji Hospital class: OTHER briefSummary: Exploring the 90% effective dose (ED90) of fospropofol disodium in induction and maintenance of anesthesia in adults of different ages, providing more clinical evidence for the application of fospropofol disodium in clinical anesthesia conditions: Elective Surgery studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 330 type: ESTIMATED name: fospropofol measure: Sedation score measure: Postoperative adverse reactions sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji hospital city: Wuhan state: Hubei zip: 430030 country: China name: Aijun Xu, Dr. role: CONTACT phone: +8618627784217 email: ajxu@tjh.tjmu.edu.cn lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06344312 id: M2023551 briefTitle: Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-01 date: 2025-01-01 date: 2025-06-01 date: 2024-04-03 date: 2024-04-03 name: Peking University Third Hospital class: OTHER briefSummary: Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism conditions: Stroke, Acute Ischemic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Yangxue Qingnao Granules measure: The proportion of subjects with mRS score ≤ 1 on the 90th day of treatment sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Third Hospital city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06344299 id: HuaDong Hosiptal of FUDAN briefTitle: Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma overallStatus: COMPLETED date: 2023-01-01 date: 2023-06-30 date: 2023-09-30 date: 2024-04-03 date: 2024-04-03 name: Fudan University class: OTHER briefSummary: More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low. Clinical workers need to take more attention to oncologic care in this group. It's significant to explore potential predictors for impacting elderly patients chose to abandon surgical resection. conditions: Pancreatic Ductal Adenocarcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 5302 type: ACTUAL name: potential predictors measure: ORs of potential predictors measure: Overall survival (OS) sex: ALL minimumAge: 75 Years maximumAge: 100 Years stdAges: OLDER_ADULT facility: Huadong Hospital affiliated to Fudan University city: Shanghai zip: 200040 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06344286 id: IstanbulTRH-DArman-002 briefTitle: The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE overallStatus: COMPLETED date: 2020-09-01 date: 2022-08-31 date: 2022-10-31 date: 2024-04-03 date: 2024-04-03 name: Istanbul Training and Research Hospital class: OTHER_GOV briefSummary: The goal of this clinical trial is to evaluate the effects of minimal enteral nutrition (MEN) on mesenteric blood flow and oxygenation with Doppler USG and Near Infrared Spectroscopy (NIRS) during therapeutic hypo¬thermia (TH) in babies with hypoxic ischemic encephalopathy. The main question it aims to answer is:
1- How do the mesenteric blood flow and oxygenation get affected with MEN during TH? Participants will be either fed with MEN during TH or given placebo. conditions: Hypoxic-Ischemic Encephalopathy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: An enteral intake of breast milk with a volume of 10-20 mL/kg/day was defined as minimal enteral feeding. Minimal enteral feeding was initiated at postnatal 24 hours with breast milk via an orogastric tube. A total daily intake of 120 ml/kg/day was defined as full enteral feeding.
The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: The feeding materials were prepared inside an opaque syringe and serially numbered by Total Parenteral Nutrition Department in our institution. The investigators who made all measurements, examinations and collected data, and the nurses of the babies were blinded. All of the infants in the study group were fed with breast milk during the trial. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: Minimal enteral nutrition name: Distilled water measure: Cerebral and mesenteric blood flow velocities and oxygenation measure: Cerebral and mesenteric rSO2 values measure: Development of NEC measure: Feeding intolerance measure: Time to full enteral feeding sex: ALL minimumAge: 0 Days maximumAge: 1 Day stdAges: CHILD facility: IstanbulTRH city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06344273 id: Burcu01 briefTitle: The Effect of Lower Extremity ROM Exercises on Hypotension, Fatigue, and Hemodialysis Comfort in Individuals overallStatus: COMPLETED date: 2023-07-01 date: 2023-08-01 date: 2023-10-01 date: 2024-04-03 date: 2024-04-03 name: Duzce University class: OTHER briefSummary: Range of motion (ROM) is a term used to describe the amount of motion in each joint in our body. Every joint in the body has a normal range of motion. Maintaining the normal opening of the joints is achieved through movement. ROM exercises reduce contractures and are very important in terms of helping to preserve muscle movements. ROM exercises are an inexpensive method that can be applied in any environment, either as a group or individually, covering all muscle-joint groups. Individuals with disabilities can perform ROM exercises individually or receive support from healthcare professionals. It provides support to venous return by increasing muscle strength in patients who are immobilized for a long time.
The patients will be divided into the intervention group (n=32) in which 20 minutes of ROM exercise was applied and the control group (n=32) in which routine nursing care was given. For the sample calculation of the study, G power analysis was performed, type 1 error was 0.05; type 2 error 0.20; With a power of 0.80, a minimum sample size of 64 people for the experimental and control groups. The case group will be given lower extremity ROM exercises for a total of two weeks. Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session. "Piper's Fatigue Scale" and Hemodialysis Comfort Scale" in the data collection form will be applied again at the end of the 1st and 2nd weeks after the sessions have started. The vital signs of the individual will be followed and recorded at each session. conditions: Hemodialysis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The patients will be divided into the intervention group (n=32) in which 20 minutes of ROM exercise was applied and the control group (n=32) in which routine nursing care was given. For the sample calculation of the study, G power analysis was performed, type 1 error was 0.05; type 2 error 0.20; With a power of 0.80, a minimum sample size of 64 people for the experimental and control groups. The case group will be given lower extremity ROM exercises for a total of two weeks. Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session. "Piper's Fatigue Scale" and Hemodialysis Comfort Scale" in the data collection form will be applied again at the end of the 1st and 2nd weeks after the sessions have started. The vital signs of the individual will be followed and recorded at each session. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: You are completely free to participate in the research or not. Not participating in this research will certainly not affect the service you receive. You have the right to withdraw from the study at any time by giving notice; you may also be excluded from the study by the investigator, if deemed necessary, provided that no harm is done to your medical condition.
If you participate in the research, you will not be charged or paid any fees for the expenses to be made in the study. In addition, at the end of the research, your information will only serve scientific purposes without revealing your identity. whoMasked: PARTICIPANT count: 70 type: ACTUAL name: ROM exercises measure: follow-up form measure: Piper Fatigue Scale measure: comfort condition sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duzce University city: Düzce zip: 81000 country: Turkey lat: 40.83889 lon: 31.16389 hasResults: False
nctId: NCT06344260 id: hNSCALSII briefTitle: Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS) acronym: STEMALS overallStatus: RECRUITING date: 2024-01-25 date: 2027-03 date: 2027-09 date: 2024-04-03 date: 2024-04-03 name: Casa Sollievo della Sofferenza IRCCS class: OTHER name: Ministry of Health, Italy briefSummary: A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo controlled, triple blind study.
This is an approximate 24-months study (PHASE B) consisting, per patient, of a 30-day screening period, 12-month enrollment and follow up period. A preliminary 3+3 dose-escalation open-label phase (PHASE A) will be performed in order to test the toxicity of the two proposed cell doses. The study will be stopped when all the subjects included in the treatment period complete the study visits. The study uses an ATMP, for that reason all the patients follow up will be prosecuted long life. conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is an approximate 24-months triple-blinded, randomized, controlled vs placebo, in three arms study (PHASE B). A preliminary 3+3 dose-escalation open-label phase (PHASE A) will be performed in order to test the toxicity of the two proposed cell doses.
In the phase B three arms will be: 1) hNSCs 20 milion cells 2) hNSCs 40 milion cells 3) Saline (comparator) primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: In order to blind also the statistician that will analyse the results the protocol has been designed as a triple-blinded protocol. This means that both the researchers, which include neurologist, neurosurgeon and biologist, as well as the patients and the statisticians are unaware of whether the participant received the treatment or the placebo (only IMP Manufacturer QP is unblinded since release the cell drug to the use in the surgery room) whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: human Neural Stem Cells (hNSC) name: Saline (Placebo) measure: Safety of treatment measure: Biological Endpoints sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Casa Sollievo Della Sofferenza IRCCS status: NOT_YET_RECRUITING city: San Giovanni Rotondo state: Foggia zip: 71013 country: Italy lat: 41.70643 lon: 15.7277 facility: Centro SLA Azienda Ospedaliera Università Maggiore della Carità status: RECRUITING city: Novara zip: 28100 country: Italy name: Letizia Mazzini, MD role: CONTACT phone: +39 0321 3733962 email: ambulatorio.sla@maggioreosp.novara.it lat: 45.44694 lon: 8.62118 facility: Azienda Ospedaliera di Padova status: NOT_YET_RECRUITING city: Padua zip: 35128 country: Italy name: Gianni Sorarù, MD role: CONTACT phone: +39049-8213645/646 email: cl.neurologica@aopd.veneto.it lat: 45.40797 lon: 11.88586 facility: Azienza Ospedaliera Universitaria - Policlinico "P. Giaccone" Università degli Studi di Palermo status: NOT_YET_RECRUITING city: Palermo zip: 90129 country: Italy name: Vincenzo La Bella, MD role: CONTACT phone: +39 091 6555158 email: info@centroslapalermo.it lat: 38.13205 lon: 13.33561 hasResults: False
nctId: NCT06344247 id: IIT-2023-0253 briefTitle: Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease overallStatus: RECRUITING date: 2023-09-01 date: 2025-09-01 date: 2025-12-01 date: 2024-04-03 date: 2024-04-03 name: RenJi Hospital class: OTHER briefSummary: The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA).
The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw). conditions: Obesity conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: RAS inhibitors：Losartan®️/Valsartan®️ name: dapagliflozin：Forxiga®️ name: simagliptin：Forxiga®️ measure: Change of 24-hour urine protein quantification measure: Decline in glomerular filtration rate measure: Changes in BMI measure: changes in fasting blood glucose sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine status: RECRUITING city: Shanghai state: Shanghai zip: 200127 country: China name: wei jin role: CONTACT phone: +8615026696535 email: jinwei_xj@126.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06344234 id: 0049191 briefTitle: Non-invasive Assessment of Inspiratory Effort and Tidal Distension During Non-invasive Ventilation (INSPIRE) acronym: INSPIRE overallStatus: RECRUITING date: 2023-11-01 date: 2026-05-01 date: 2026-06-01 date: 2024-04-03 date: 2024-04-03 name: University of Bari class: OTHER briefSummary: The goal of this observational study is to evaluate whether the airway occlusion pressure recorded during a sudden end-expiratory breath-hold (ΔPocc) is correlated with esophageal swing in pressure and the reliability of P0.1, driving pressure, plateau pressure, pressure-muscle index, and diaphragm ultrasound as noninvasive estimates of inspiratory effort and lung distension in hypoxemic patients undergoing NIV.
* Diaphragm ultrasound during occlusion maneuvers, measuring diaphragm displacement, diaphragm thickening fraction (DTF%), and diaphragmatic excursion (Ex) under various conditions. conditions: Respiratory Disease conditions: Artificial Respiration studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: End-inspiratory Maneuvers measure: Statistic metric of association between ΔPocc and ΔPes measure: Statistic metric of association between P0.1, ΔP, PMI and ΔPes measure: Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and PaO2/FiO2 ratio measure: Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and tidal volume measure: Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and DTF% measure: Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and Ex/DTF% measure: Statistic metric of association between P0.1, ΔPocc, ΔP, PMI and respiratory rate, VAS dyspnea and VAS discomfort measure: Reliability of various noninvasive estimates of inspiratory effort and lung distension in hypoxemic patients undergoing NIV sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda ospedaliero-universitaria consorziale policlinico di Bari status: RECRUITING city: Bari zip: 70124 country: Italy name: Salvatore Grasso, MD, Professor role: CONTACT email: salvatore.grasso@uniba.it name: Francesco Murgolo, MD role: PRINCIPAL_INVESTIGATOR name: Domenico Luca Grieco, MD role: PRINCIPAL_INVESTIGATOR lat: 41.11148 lon: 16.8554 hasResults: False